ROIVANT SCIENCES LTD. Revenue
ROIVANT SCIENCES LTD. (ROIV) reported Revenue of $1.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.44M, a 33.55% decline year-over-year.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.52M, a 66.71% decline year-over-year.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $2.00M, a 77.83% decline year-over-year.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.57M, a 64.89% decline year-over-year.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2026 was $8.26M, a 71.57% decline from fiscal 2025.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $29.05M, a 11.19% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $32.71M, a 3.75% increase from fiscal 2023.
- ROIVANT SCIENCES LTD. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $31.53M, a 42.97% decline from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-06 | $3.96M derived: sum of 2 quarters · filed 2026-08-06 | $5.96M derived: sum of 3 quarters · filed 2026-08-06 | $7.53M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $4.52M derived: sum of 2 quarters · filed 2026-05-20 | $6.09M derived: sum of 3 quarters · filed 2026-05-20 | $8.26M 10-K · filed 2026-05-20 | ||||
| 2025-12-31 | $2.00M 10-Q · filed 2026-02-06 | $3.57M derived: sum of 2 quarters · filed 2026-02-06 | $5.74M 10-Q · filed 2026-02-06 | $13.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-09-30 | $1.57M 10-Q · filed 2025-11-10 | $3.74M 10-Q · filed 2025-11-10 | $11.31M derived: sum of 3 quarters · filed 2026-08-06 | $20.33M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.17M 10-Q · filed 2026-08-06 | $9.74M derived: sum of 2 quarters · filed 2026-08-06 | $18.76M derived: sum of 3 quarters · filed 2026-08-06 | $23.23M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $16.59M derived: sum of 2 quarters · filed 2026-05-20 | $21.06M derived: sum of 3 quarters · filed 2026-05-20 | $29.05M 10-K · filed 2026-05-20 | ||||
| 2024-12-31 | $9.02M 10-Q · filed 2026-02-06 | $13.49M derived: sum of 2 quarters · filed 2026-02-06 | $21.48M 10-Q · filed 2026-02-06 | $30.50M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-09-30 | $4.47M 10-Q · filed 2025-11-10 | $12.46M 10-Q · filed 2025-11-10 | $21.48M derived: sum of 3 quarters · filed 2026-05-20 | $37.05M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-06-30 | $7.99M 10-Q · filed 2025-08-11 | $55.13M 10-Q · filed 2024-08-09 | $17.01M derived: sum of 2 quarters · filed 2026-05-20 | $32.57M derived: sum of 3 quarters · filed 2026-05-20 | $36.22M derived: sum of 4 quarters · filed 2026-05-20 | |||
| 2024-03-31 | $9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $24.58M derived: sum of 2 quarters · filed 2026-05-20 | $28.23M derived: sum of 3 quarters · filed 2026-05-20 | $32.71M 10-K · filed 2026-05-20 | $124.80M 10-K · filed 2024-05-30 | |||
| 2023-12-31 | $15.56M 10-Q · filed 2025-02-10 | $37.14M 10-Q · filed 2024-02-13 | $19.21M derived: sum of 2 quarters · filed 2025-02-10 | $23.69M 10-Q · filed 2025-02-10 | $95.86M 10-Q · filed 2024-02-13 | $38.46M derived: sum of 4 quarters · filed 2025-05-29 | ||
| 2023-09-30 | $3.65M 10-Q · filed 2024-11-12 | $37.10M 10-Q · filed 2023-11-13 | $8.13M 10-Q · filed 2024-11-12 | $58.73M 10-Q · filed 2023-11-13 | $22.90M derived: sum of 3 quarters · filed 2025-05-29 | $39.95M derived: sum of 4 quarters · filed 2025-05-29 | ||
| 2023-06-30 | $21.62M 10-Q · filed 2024-08-09 | $19.25M derived: sum of 2 quarters · filed 2025-05-29 | $36.30M derived: sum of 3 quarters · filed 2025-05-29 | $48.84M derived: sum of 4 quarters · filed 2025-05-29 | ||||
| 2023-03-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $14.68M derived: sum of 2 quarters · filed 2025-05-29 | $27.21M derived: sum of 3 quarters · filed 2025-05-29 | $31.53M 10-K · filed 2025-05-29 | $61.28M 10-K · filed 2023-06-28 | |||
| 2022-12-31 | $17.05M 10-Q · filed 2024-02-13 | $29.59M derived: sum of 2 quarters · filed 2024-02-13 | $33.90M 10-Q · filed 2024-02-13 | $43.13M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | $12.53M 10-Q · filed 2023-11-13 | $16.85M 10-Q · filed 2023-11-13 | $26.07M derived: sum of 3 quarters · filed 2023-11-13 | $50.42M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $4.32M 10-Q · filed 2023-08-14 | $13.54M derived: sum of 2 quarters · filed 2023-08-14 | $37.88M derived: sum of 3 quarters · filed 2023-08-14 | $51.87M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $9.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $33.56M derived: sum of 2 quarters · filed 2023-06-28 | $47.55M derived: sum of 3 quarters · filed 2023-06-28 | $55.29M 10-K · filed 2023-06-28 | ||||
| 2021-12-31 | $24.34M 10-Q · filed 2023-02-13 | $38.33M derived: sum of 2 quarters · filed 2023-02-13 | $46.06M 10-Q · filed 2023-02-13 | $61.21M derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2021-09-30 | $13.99M 10-Q · filed 2022-11-14 | $21.72M 10-Q · filed 2022-11-14 | $36.87M derived: sum of 3 quarters · filed 2022-11-14 | $42.62M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $7.74M 10-Q · filed 2022-08-15 | $22.88M derived: sum of 2 quarters · filed 2022-08-15 | $28.63M derived: sum of 3 quarters · filed 2022-08-15 | $29.95M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $15.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $20.90M derived: sum of 2 quarters · filed 2022-06-28 | $22.22M derived: sum of 3 quarters · filed 2022-06-28 | $23.80M 10-K · filed 2022-06-28 | ||||
| 2020-12-31 | $5.75M 10-Q · filed 2022-02-14 | $7.07M derived: sum of 2 quarters · filed 2022-02-14 | $8.65M 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | $1.32M 10-Q · filed 2021-11-15 | $2.90M 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $1.58M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |